Published in Clin Chem on October 05, 2007
Ets-2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long non-coding RNA, in bladder cancer cells. PLoS One (2013) 1.11
Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline. PLoS One (2014) 1.06
Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol (2009) 1.03
Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther (2013) 0.96
External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiol Biomarkers Prev (2014) 0.87
Transcriptional repression of Caveolin-1 (CAV1) gene expression by GATA-6 in bladder smooth muscle hypertrophy in mice and human beings. Am J Pathol (2011) 0.85
Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. Curr Med Chem (2012) 0.83
UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria. Oncotarget (2016) 0.76
A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer. Cancer Epidemiol Biomarkers Prev (2016) 0.76
Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise. Indian J Urol (2015) 0.75
Extracellular Nucleic Acids in Urine: Sources, Structure, Diagnostic Potential. Acta Naturae (2015) 0.75
A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol (2009) 3.59
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA (2003) 3.45
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol (2004) 2.23
Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Eur Urol (2008) 2.06
Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res (2006) 1.52
Anterior chamber angle measurement with optical coherence tomography: intraobserver and interobserver variability. J Cataract Refract Surg (2006) 1.43
Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. J Urol (2003) 1.33
Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol (2009) 1.32
Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA (2006) 1.29
Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int (2005) 1.27
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol (2010) 1.24
Internal limiting membrane peeling with indocyanine green or trypan blue in macular hole surgery: a randomized trial. Arch Ophthalmol (2007) 1.08
Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol (2004) 1.03
Outcome analysis of fornix ruptures in 162 consecutive patients. J Endourol (2010) 1.02
TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging (2007) 1.02
Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol (2002) 0.93
Destruction of stone extraction basket during an in vitro lithotripsy--a comparison of four lithotripters. J Endourol (2011) 0.93
Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma. Oncology (2005) 0.93
Interstitial biodegradable balloon for reduced rectal dose during prostate radiotherapy: results of a virtual planning investigation based on the pre- and post-implant imaging data of an international multicenter study. Radiother Oncol (2013) 0.91
Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer (2003) 0.90
Primitive neuroectodermal tumor (PNET) of the urinary bladder. Pathol Res Pract (2003) 0.90
Application of an interstitial and biodegradable balloon system for prostate-rectum separation during prostate cancer radiotherapy: a prospective multi-center study. Radiat Oncol (2013) 0.89
P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol (2005) 0.88
Effects of covariates: a summary of Group 5 contributions. Genet Epidemiol (2003) 0.88
Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging (2009) 0.87
Effects of verteporfin therapy on central visual field function. Ophthalmology (2004) 0.87
Prostate cancer vaccines: current status and future potential. BioDrugs (2008) 0.86
Giant bladder diverticulum as a rare cause of intestinal obstruction: report of a case. Surg Today (2007) 0.86
Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res (2005) 0.85
The role of surgery in clinical management of patients with metastatic papillary renal cell carcinoma. J Cancer Res Clin Oncol (2009) 0.84
Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo. Int J Oncol (2010) 0.84
Improved conditions for isolation and quantification of RNA in urine specimens. Ann N Y Acad Sci (2004) 0.83
First clinical experience with extracorporeally induced destruction of kidney stones by shock waves. 1981. J Urol (2002) 0.83
Laparoscopic adrenalectomy in urological centres - the experience of the German Laparoscopic Working Group. BJU Int (2011) 0.82
Drug evaluation: Degarelix--a potential new therapy for prostate cancer. IDrugs (2006) 0.82
Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition. BJU Int (2005) 0.82
mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep (2011) 0.82
E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder. Oncol Rep (2005) 0.81
The use of cryopreserved mature and immature testicular spermatozoa for intracytoplasmic sperm injection: risks and limitations. Semin Reprod Med (2002) 0.81
Technology evaluation: Onyvax-P, Onyvax. Curr Opin Mol Ther (2005) 0.80
Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology (2006) 0.80
Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol (2008) 0.80
Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications. Anticancer Res (2005) 0.79
Degarelix for prostate cancer. Expert Opin Investig Drugs (2009) 0.79
Papillary urothelial bladder carcinoma associated with osteoclast-like giant cells. Int Urol Nephrol (2005) 0.78
Does adjuvant vitespen prevent recurrence in patients with locally advanced kidney cancer? Nat Clin Pract Urol (2008) 0.77
Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine. Curr Opin Mol Ther (2007) 0.77
Degarelix and its therapeutic potential in the treatment of prostate cancer. Clin Interv Aging (2009) 0.77
In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer. In Vivo (2009) 0.77
Cytokine and vaccine therapy of kidney cancer. Expert Rev Anticancer Ther (2004) 0.77
Investigation of the origin of extracellular RNA in human cell culture. Ann N Y Acad Sci (2006) 0.77
Midterm results of the Ross procedure preserving the patient's aortic root. Circulation (2003) 0.77
Subcoronary Ross procedure in patients with active endocarditis. Ann Thorac Surg (2007) 0.76
Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?! J Cancer Res Clin Oncol (2014) 0.76
[Quality of life after radical cystectomy - an overview and analysis of a contemporary series]. Aktuelle Urol (2010) 0.76
Damage of stone baskets by endourologic lithotripters: a laboratory study of 5 lithotripters and 4 basket types. Adv Urol (2013) 0.75
[Editorial comment on Stepp H. et al.: fluorescence diagnosis and photodynamic therapy in urology]. Aktuelle Urol (2007) 0.75
Could titanium oxide coating from a sol-gel process make stone baskets more resistant to laser radiation at 2.1 μm? J Negat Results Biomed (2012) 0.75
Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/Millennium. Curr Opin Mol Ther (2002) 0.75
Mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder. Urology (2006) 0.75
Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer. Expert Rev Anticancer Ther (2006) 0.75
Stone/tissue differentiation during intracorporeal lithotripsy using diffuse white light reflectance spectroscopy: In vitro and clinical measurements. Lasers Surg Med (2014) 0.75
Ki-67 protein concentrations in urothelial bladder carcinomas are related to Ki-67-specific RNA concentrations in urine. Clin Chem (2004) 0.75
Technology evaluation: PROSTVAC, Therion. Curr Opin Mol Ther (2002) 0.75
Results of secondary ureteral implantation after kidney transplantation. Int Urol Nephrol (2011) 0.75
Investigation of bladder deformability within the development process of the artificial urinary diversion system - a pilot study. Int J Artif Organs (2011) 0.75
Gene and antisense therapy of bladder cancer. Adv Exp Med Biol (2003) 0.75
First clinical experience with extracorporeally induced destruction of kidney stones by shock waves. 1981. J Urol (2002) 0.75
Comparison between a 1.92-μm fiber laser and a standard HF-dissection device for nephron-sparing kidney resection in a porcine in vivo study. Lasers Med Sci (2011) 0.75
The role of LFA-1 in the lysis of bladder cancer cells by bacillus Calmette-Guérin and interleukin 2-activated killer cells. Urol Res (2002) 0.75
Pulmonary homograft muscle reduction to reduce the risk of homograft stenosis in the Ross procedure. J Thorac Cardiovasc Surg (2007) 0.75